Next generation oncology drug development: opportunities and challenges (Q37458170)

20 August 2017

1 reference

title

Next generation oncology drug development: opportunities and challenges (English)

1 reference

20 August 2017

3

Giuseppe Giaccone

1 reference

20 August 2017

Martin E Gutierrez

1

1 reference

20 August 2017

Shivaani Kummar

series ordinal

2

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 May 2009

1 reference

Nature Reviews Clinical Oncology

20 August 2017

1 reference

20 August 2017

6

1 reference

20 August 2017

259-265

1 reference

20 August 2017

5

1 reference

https://scigraph.springernature.com/pub.10.1038/nrclinonc.2009.38

20 August 2017

0 references

cites work

A Clinical Trial Design Avoiding Undue Placebo Treatment

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.38

Can the pharmaceutical industry reduce attrition rates?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.38

Drug development in oncology: classical cytotoxics and molecularly targeted agents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.38

Clinical trial design for target-based therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.38

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.38

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.38

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.38

Measuring Response in Solid Tumors: Comparison of RECIST and WHO Response Criteria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.38

Selection of response criteria for clinical trials of sarcoma treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.38

Rethinking clinical trials for cytostatic drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.38

Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.38

A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.38

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.38

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.38

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.38

Bevacizumab in the treatment of breast cancer: rationale and current data

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.38

Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.38

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.38

Specific targeted therapy of chronic myelogenous leukemia with imatinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.38

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.38

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.38

Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.38

Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.38

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.38

Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.38

Strategies for optimizing combinations of molecularly targeted anticancer agents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.38

Human multidrug transporter ABCG2, a target for sensitizing drug resistance in cancer chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.38

Randomized discontinuation trials: Utility and efficiency

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.38

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.38

Sorafenib in advanced clear-cell renal-cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.38

Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.38

Evaluation of randomized discontinuation design

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.38

Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.38

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.38

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.38

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.38

Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.38

Compressing drug development timelines in oncology using phase '0' trials.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.38

Designing phase 0 cancer clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.38

Imaging and other biomarkers in early clinical studies: one step at a time or re-engineering drug development?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.38

Targeted therapy: wave of the future.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.38

Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19390552

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19390552

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCLINONC.2009.38

1 reference

Dimensions Publication ID

20 August 2017

0 references

0 references

1 reference